TSX higher on employment data
NEW YORK - Glaukos Corporation (NYSE:GKOS) shares plunged 12.9% after the ophthalmic medical technology company reported a wider-than-expected fourth quarter loss, overshadowing better-than-anticipated revenue.
The company posted an adjusted loss of $0.40 per share for Q4, $0.02 worse than analysts’ estimates of a $0.38 per share loss. Revenue came in at $105.5 million, surpassing expectations of $100.53 million and rising 28% YoY.
"Our record fourth quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond," said Thomas Burns, Glaukos chairman and chief executive officer.
For the full year 2024, Glaukos reported net sales of $383.5 million, up 22% compared to 2023.
Looking ahead, the company provided 2025 revenue guidance of $475 million to $485 million, in line with the consensus estimate of $480.3 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.